👤 Serina Huang

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
1370
Articles
1004
Name variants
Also published as: Ai-Chun Huang, Ai-long Huang, Aijie Huang, Ailong Huang, Aimin Huang, Alden Y Huang, An-Fang Huang, Annie Huang, Aohuan Huang, Ariane Huang, Baihai Huang, Baisong Huang, Bao-Hua Huang, Bao-Yi Huang, Baoqin Huang, Baoying Huang, Benjamin J Huang, Benlin Huang, Bevan E Huang, Bi Huang, Biao Huang, Bin Huang, Binfang Huang, Bing Huang, Bingcang Huang, Bingkun Huang, Bizhi Huang, Bo Huang, Bo-Shih Huang, Bor-Ren Huang, Bowen Huang, Boyue Huang, C Y Huang, Caihong Huang, Caiyun Huang, Can Huang, Canhua Huang, Caoxin Huang, Cathelin Huang, Catherine Huang, Chang Ming Huang, Chang X Huang, Chang-Jen Huang, Changjiang Huang, Chao Huang, Chao Wei Huang, Chao-Wei Huang, Chao-Yuan Huang, Chaolin Huang, Chaoqun Huang, Chaowang Huang, Chaoyang Huang, Chen Huang, Chen-Na Huang, Chen-Ping Huang, Cheng Huang, Chengcheng Huang, Chengrui Huang, Chenshen Huang, Chenxiao Huang, Chi-Cheng Huang, Chi-Shuan Huang, Chia-Chang Huang, Chia-Wei Huang, Chieh-Cheng Huang, Chieh-Liang Huang, Chien-Hsun Huang, Chih-Chun Huang, Chih-Hsiang Huang, Chih-Jen Huang, Chih-Ting Huang, Chih-Yang Huang, Chin-Chang Huang, Chin-Chou Huang, Ching-Shan Huang, Ching-Shin Huang, Ching-Tang Huang, Ching-Wei Huang, Chiu-Ju Huang, Chiu-Jung Huang, Chiun-Sheng Huang, Chong Huang, Chongbiao Huang, Christine S Huang, Chuan Huang, Chuanbing Huang, Chuanhong Huang, Chuanjiang Huang, Chuanjun Huang, Chuansheng Huang, Chuiguo Huang, Chun Huang, Chun-Mei Huang, Chun-Yao Huang, Chun-Yin Huang, Chunfan Huang, Chung-Hsiung Huang, Chunhong Huang, Chunjian Huang, Chunkai Huang, Chunlan Huang, Chunling Huang, Chunshuai Huang, Chunxia Huang, Chunyao Huang, Chunyi Huang, Chunying Huang, Chunyu Huang, Chuxin Huang, Chuying Huang, Congcong Huang, Cuiyu Huang, Da Huang, Dajun Huang, Dan Huang, Dane Huang, Danqing Huang, Dantong Huang, David Huang, David J Huang, De Huang, De-Jun Huang, Dejia Huang, Dengjun Huang, Dianhua Huang, Dishu Huang, Dong Huang, Donglan Huang, Dongmei Huang, Dongni Huang, Dongqin Huang, Dongqing Huang, Dongsheng Huang, Dongyu Huang, Du-Juan Huang, Emily C Huang, Enhao Huang, Enping Huang, Eric Huang, Erya Huang, F Huang, Fan Huang, Fang Huang, Fang-Ling Huang, Fangling Huang, Fei Huang, Fei Wan Huang, Feiruo Huang, Feiteng Huang, Feizhou Huang, Feng Huang, Fengxian Huang, Fengyu Huang, Franklin W Huang, Fu-Chen Huang, Fu-Mei Huang, Fubiao Huang, Fude Huang, Fuhao Huang, Furong Huang, G Huang, Gairong Huang, Gang Huang, Gao-Zhong Huang, Gaoxingyu Huang, Ge Huang, Guang-Jian Huang, Guang-Yun Huang, Guangjian Huang, Guangming Huang, Guangqian Huang, Guangrui Huang, Guanhong Huang, Guanling Huang, Guanning Huang, Guanqun Huang, Guanrong Huang, Guicheng Huang, Guodong Huang, Guohong Huang, Guoping Huang, Guoqian Huang, Guowei Huang, Guoxing Huang, Guoying Huang, Guoyong Huang, Guoyuan Huang, H Huang, H S Huang, Hai Huang, Haigang Huang, Haihong Huang, Hailin Huang, Haimiao Huang, Haixin Huang, Haiyan Huang, Han-Chang Huang, Hanxia Huang, Hao Huang, Hao-Fei Huang, Haobo Huang, Haochu Huang, Haomin Huang, Haoyu Huang, Haoyue Huang, Haozhang Huang, Haozhong Huang, He Huang, Hefeng Huang, Heguang Huang, Helen Huang, Heming Huang, Hengbin Huang, Heqing Huang, Hete Huang, Hong Huang, Hongbiao Huang, Hongcan Huang, Hongda Huang, Hongfei Huang, Hongfeng Huang, Honghui Huang, Hongou Huang, Hongqiang Huang, Hongyan Huang, Hongyang Huang, Hongyi Huang, Hongying Huang, Hongyu Huang, Hongyun Huang, Hsi-Yuan Huang, Hsien-Da Huang, Hsing-Yen Huang, Hsu Chih Huang, Hsuan-Cheng Huang, Hsuan-Ying Huang, Hu Huang, Hua Huang, Huafei Huang, Huaju Huang, Huan Huang, Huanhuan Huang, Huanliang Huang, Huapin Huang, Huashan Huang, Huayun Huang, Hui Huang, Hui-Huang Huang, Hui-Kuang Huang, Hui-Yu Huang, Huibin Huang, Huifen Huang, Huiling Huang, Huimin Huang, Huina Huang, Huiqiao Huang, Huixian Huang, Huixin Huang, Huiyan Huang, Huiyu Huang, Huizhe Huang, Huizhen Huang, Hy Huang, I-Chieh Huang, J V Huang, Janice J Huang, Jasmin Huang, Jeffrey K Huang, Jia Huang, Jia-Jia Huang, Jiaan Huang, Jiahui Huang, Jiajin Huang, Jiajun Huang, Jian Huang, Jian-Dong Huang, Jiana Huang, Jianbiao Huang, Jianbing Huang, Jianfang Huang, Jianfeng Huang, Jiangfeng Huang, Jiangtao Huang, Jiangwei Huang, Jianhua Huang, Jianlu Huang, Jianmin Huang, Jianming Huang, Jiansheng Huang, Jianzhen Huang, Jiao-Qian Huang, Jiaoti Huang, Jiaotian Huang, Jiaqi Huang, Jiawen Huang, Jiaxing Huang, Jiayu Huang, Jiayue Huang, Jie Huang, Jie Qi Huang, Jiechun Huang, Jieli Huang, Jieling Huang, Jieping Huang, Jin Huang, Jin-Di Huang, Jin-Feng Huang, Jin-Hong Huang, Jin-Yan Huang, Jinbao Huang, Jinfang Huang, Jing Huang, Jing-Fei Huang, Jingang Huang, Jinghan Huang, Jingjing Huang, Jingkun Huang, Jinglong Huang, Jingtao Huang, Jingxian Huang, Jingyong Huang, Jingyuan Huang, Jingyue Huang, Jinhua Huang, Jinling Huang, Jinlu Huang, Jinshu Huang, Jinxing Huang, Jinyan Huang, Jinzhou Huang, Jiuhong Huang, Jiyu Huang, Ju Huang, Juan Huang, Jucun Huang, Jun Huang, Jun-Hua Huang, Jun-You Huang, Junhao Huang, Junhua Huang, Junjie Huang, Junming Huang, Junning Huang, Junqi Huang, Junwen Huang, Junyuan Huang, Junyun Huang, Juxiang Huang, K Huang, K N Huang, Kai Huang, Kaipeng Huang, Kang Huang, Kangbo Huang, Kate Huang, Katherine Huang, Ke Huang, Ke-Ke Huang, Ke-Pu Huang, Kevin Huang, Kevin Y Huang, Kuan-Chun Huang, Kui-Yuan Huang, Kuiyuan Huang, Kun Huang, Kuo-Hsiang Huang, Kuo-Hung Huang, L Huang, L-B Huang, Laiqiang Huang, Lan Huang, Lanlan Huang, Lei Huang, Leijuan Huang, Li Huang, Li-Hao Huang, Li-Jiang Huang, Li-Juan Huang, Li-Jun Huang, Li-Ping Huang, Li-Rung Huang, Li-Wei Huang, Li-Yun Huang, Lian Huang, Liang Huang, Liang-Yu Huang, Liangchong Huang, Lianggui Huang, Libin Huang, Lige Huang, Lihua Huang, Lijia Huang, Lijiang Huang, Lijuan Huang, Lijun Huang, Lili Huang, Limin Huang, Liming Huang, Lin Huang, Linchen Huang, Ling Huang, Ling-Chun Huang, Ling-Jin Huang, Lingling Huang, Lining Huang, Linjing Huang, Linsheng Huang, Linxue Huang, Linyuan Huang, Liping Huang, Liqiong Huang, Lixia Huang, Lixiang Huang, Lixuan Huang, Lixue Huang, Lizhen Huang, Longfei Huang, Lu Huang, Lu-Jie Huang, Lu-Qi Huang, Luanluan Huang, Luqi Huang, Luyang Huang, Luyao Huang, Lvzhen Huang, M C Huang, Man Huang, Manning Y Huang, Manyun Huang, Mao-Mao Huang, Mei Huang, Meihua Huang, Meina Huang, Meixiang Huang, Melissa Y Huang, Meng-Chuan Huang, Meng-Fan Huang, Meng-Na Huang, MengQian Huang, Menghao Huang, Mengjie Huang, Mengjun Huang, Mengnan Huang, Mengting Huang, Mengzhen Huang, Mia L Huang, Miao Huang, Min Huang, Ming-Lu Huang, Ming-Shyan Huang, Mingjian Huang, Mingjun Huang, Minglei Huang, Mingrui Huang, Mingwei Huang, Mingxuan Huang, Mingyu Huang, Mingyuan Huang, Minjun Huang, Minqi Huang, Minxuan Huang, Minyuan Huang, N Huang, Na Huang, Nian Huang, Nianyuan Huang, Ning-Na Huang, Ning-Ping Huang, Ninghao Huang, Nongyu Huang, Pan Huang, Pang-Shuo Huang, Paul L Huang, Pei Huang, Pei-Chi Huang, Pei-Ying Huang, Peiying Huang, Peng Huang, Peng-Fei Huang, Pengyu Huang, Piao-Piao Huang, Piaopiao Huang, Pin-Rui Huang, Ping Huang, Pingping Huang, Pintong Huang, Po-Hsun Huang, Po-Jung Huang, Poyao Huang, Qi Huang, Qi-Tao Huang, Qian Huang, Qiang Huang, Qianqian Huang, Qiaobing Huang, Qibin Huang, Qidi Huang, Qin Huang, Qing Huang, Qing-yong Huang, Qingjiang Huang, Qingke Huang, Qingling Huang, Qingqing Huang, Qingsong Huang, Qingxia Huang, Qingxing Huang, Qingyu Huang, Qingzhi Huang, Qinlou Huang, Qiong Huang, Qiubo Huang, Qiumin Huang, Qiuming Huang, Qiuru Huang, Qiuyin Huang, Qiuyue Huang, Qizhen Huang, Quanfang Huang, Qun Huang, R H Huang, R Stephanie Huang, Rae-Chi Huang, Ran Huang, Renbin Huang, Renhua Huang, Renli Huang, Richard Huang, Richard S P Huang, Riqing Huang, Ritai Huang, Robert J Huang, Rong Huang, Rong Stephanie Huang, Ronghua Huang, Ronghui Huang, Rongjie Huang, Rongrong Huang, Rongxiang Huang, Ru-Ting Huang, Ruby Yun-Ju Huang, Rui Huang, Ruihua Huang, Ruijin Huang, Ruina Huang, Ruiyan Huang, Ruizhen Huang, Runyue Huang, Ruo-Hui Huang, S Huang, S Y Huang, S Z Huang, Saisai Huang, San-Yuan Huang, See-Chang Huang, Sen Huang, Shan Huang, Shang-Ming Huang, Shanhe Huang, Shanshan Huang, Shaojun Huang, Shaoxin Huang, Shaoze Huang, Shau Ku Huang, Shau-Ku Huang, Shenan Huang, Sheng-He Huang, Shengfeng Huang, Shengjie Huang, Shengnan Huang, Shengyan Huang, Shengyun Huang, Shi-Feng Huang, Shi-Shi Huang, Shi-Ying Huang, Shiang-Suo Huang, Shichao Huang, Shih-Chiang Huang, Shih-Wei Huang, Shih-Yi Huang, Shihao Huang, Shijing Huang, Shilu Huang, Shixia Huang, Shiya Huang, Shiying Huang, Shiyun Huang, Shoucheng Huang, Shu Huang, Shu-Pang Huang, Shu-Pin Huang, Shu-Qiong Huang, Shu-Wei Huang, Shu-Yi Huang, Shu-ying Huang, Shuai Huang, Shuang Huang, Shungen Huang, Shuo Huang, Shushu Huang, Shutong Huang, Shuwen Huang, Si-Yang Huang, Sidong Huang, Sihua Huang, Sijia Huang, Sinchun Huang, Sisi Huang, Sixiu Huang, Song Bin Huang, Song-Mei Huang, Songmei Huang, Songming Huang, Songqian Huang, Steven Huang, Steven Kuan-Hua Huang, Suli Huang, Sung-Ying Huang, Susan M Huang, Suwen Huang, Taiqi Huang, Tang-Hsiu Huang, Tao Huang, Te-Hsuan Huang, Tengda Huang, Tengfei Huang, Tian Hao Huang, Tianhao Huang, Tianpu Huang, Tiantian Huang, Tieqiu Huang, Tim H Huang, Ting Huang, Tinghua Huang, Tingping Huang, Tingqin Huang, Tingting Huang, Tingxuan Huang, Tingyun Huang, Tong Huang, Tongsheng Huang, Tongtong Huang, Tony T Huang, Tse-Shun Huang, Tseng-Yu Huang, Tsung-Wei Huang, Tzu-Rung Huang, Wan-Ping Huang, Way-Ren Huang, Wei Huang, Wei-Chi Huang, Weibin Huang, Weicheng Huang, Weifeng Huang, Weihua Huang, Weijun Huang, Weiqi Huang, Weisu Huang, Weiwei Huang, Weixue Huang, Weizhen Huang, Wen Huang, Wen-yu Huang, Wenbin Huang, Wenda Huang, Wenfang Huang, Wenfeng Huang, Wenhua Huang, Wenji Huang, Wenjie Huang, Wenjun Huang, Wenqiao Huang, Wenqing Huang, Wenqiong Huang, Wenshan Huang, Wentao Huang, Wenxin Huang, Wenya Huang, Wenying Huang, Wunan Huang, Wuqing Huang, X F Huang, X Huang, Xi Huang, Xian-sheng HUANG, Xiang Huang, Xianghua Huang, Xianglong Huang, Xiangming Huang, Xianping Huang, Xianqing Huang, Xiansheng Huang, Xianwei Huang, Xianxi Huang, Xianxian Huang, Xianying Huang, Xianzhang Huang, Xiao Huang, Xiao-Fang Huang, Xiao-Fei Huang, Xiao-Ming Huang, Xiao-Song Huang, Xiao-Yan Huang, Xiao-Yong Huang, Xiao-Yu Huang, XiaoFang Huang, Xiaochun Huang, Xiaofei Huang, Xiaofeng Huang, Xiaohong Huang, Xiaohua Huang, Xiaojie Huang, Xiaojing Huang, Xiaojuan Huang, Xiaolan Huang, Xiaoli Huang, Xiaolin Huang, Xiaoman Huang, Xiaomin Huang, Xiaoqing Huang, Xiaoshuai Huang, Xiaowen Huang, Xiaowu Huang, Xiaoxia Huang, Xiaoyan Huang, Xiaoying Huang, Xiaoyu Huang, Xiaoyuan Huang, Xiaoyun Huang, Xiaozhun Huang, Xiayang Huang, Xichang Huang, Xie-Lin Huang, Xin Huang, Xin-Di Huang, Xinen Huang, Xinfeng Huang, Xingguo Huang, Xingming Huang, Xingqin Huang, Xingru Huang, Xingxu Huang, Xingya Huang, Xingzhen Huang, Xinwen Huang, Xinyi Huang, Xinying Huang, Xinyue Huang, Xinzhu Huang, Xiongfeng Huang, Xionggao Huang, Xiuju Huang, Xiuyun Huang, Xiuzhen Huang, Xiwen Huang, Xu Huang, Xu-Feng Huang, Xuan Huang, Xuanzhang Huang, Xucong Huang, Xudong Huang, Xue-Ying Huang, Xue-shuang Huang, Xuehong Huang, Xuejie Huang, Xuejing Huang, Xuejun Huang, Xuemei Huang, Xueming Huang, Xueqi Huang, Xuewei Huang, Xuezhe Huang, Xuhui Huang, Xuliang Huang, Xun Huang, Xuxiong Huang, Y Huang, Y Joyce Huang, Y S Huang, Ya-Chih Huang, Ya-Dong Huang, Ya-Fang Huang, Ya-Ru Huang, Yabo Huang, Yadong Huang, Yafang Huang, Yajiao Huang, Yajuan Huang, Yali Huang, Yamei Huang, Yan Huang, Yan-Lin Huang, Yan-Qing Huang, Yan-Ting Huang, Yang Huang, Yang Zhong Huang, Yangqing Huang, Yangyang Huang, Yanhao Huang, Yani Huang, Yanjun Huang, Yanlong Huang, Yanna Huang, Yanping Huang, Yanqin Huang, Yanqing Huang, Yanqun Huang, Yanru Huang, Yanshan Huang, Yansheng Huang, Yanxia Huang, Yanyan Huang, Yanyao Huang, Yao Huang, Yao-Kuang Huang, Yaowei Huang, Yatian Huang, Yating Huang, Ye Huang, Yechao Huang, Yen-Chu Huang, Yen-Ning Huang, Yen-Tsung Huang, Yeqing Huang, Yewei Huang, Yi Huang, Yi-Chun Huang, Yi-Jan Huang, Yi-Jia Huang, Yi-Wen Huang, Yi-ping Huang, Yichao Huang, Yichuan Huang, Yicong Huang, Yifan Huang, Yihao Huang, Yiheng Huang, Yihong Huang, Yikeng Huang, Yilin Huang, Yin Huang, Yin-Tsen Huang, Ying Huang, Ying-Hsuan Huang, Ying-Jung Huang, Ying-Zhi Huang, Yinghua Huang, Yingying Huang, Yingzhen Huang, Yingzhi Huang, Yiping Huang, Yiquan Huang, Yishan Huang, Yiwei Huang, Yixian Huang, Yizhou Huang, Yong Huang, Yong-Fu Huang, Yongbiao Huang, Yongcan Huang, Yongjie Huang, Yongqi Huang, Yongsheng Huang, Yongtong Huang, Yongye Huang, Yongyi Huang, Yongzhen Huang, Youheng Huang, Youyang Huang, Yu Huang, Yu-Ching Huang, Yu-Chu Huang, Yu-Chuen Huang, Yu-Chyi Huang, Yu-Fang Huang, Yu-Han Huang, Yu-Jie Huang, Yu-Lei Huang, Yu-Ren Huang, Yu-Shu Huang, Yu-Ting Huang, Yuan Huang, Yuan-Lan Huang, Yuan-Li Huang, Yuan-Lu Huang, Yuancheng Huang, Yuanpeng Huang, Yuanshuai Huang, Yuanyu Huang, Yuanyuan Huang, Yue Huang, Yue-Hua Huang, Yuedi Huang, Yueh-Hsiang Huang, Yuehong Huang, Yuejun Huang, Yueye Huang, Yuezhen Huang, Yufang Huang, Yufen Huang, Yuguang Huang, Yuh-Chin T Huang, Yuhong Huang, Yuhua Huang, Yuhui Huang, Yujia Huang, Yujie Huang, Yulin Huang, Yumei Huang, Yumeng Huang, Yun Huang, Yun-Juan Huang, Yunchao Huang, Yung-Hsin Huang, Yung-Yu Huang, Yunmao Huang, Yunpeng Huang, Yunru Huang, Yunyan Huang, Yuping Huang, Yuqi Huang, Yuqiang Huang, Yuqiong Huang, Yusi Huang, Yutang Huang, Yuting Huang, Yutong Huang, Yuxian Huang, Yuxin Huang, Yuxuan Huang, Yuyang Huang, Yuying Huang, Z Huang, Z Z Huang, Z-Y Huang, Zebin Huang, Zebo Huang, Zehua Huang, Zeling Huang, Zengwen Huang, Zhang Huang, Zhao Huang, Zhaoxia Huang, Zhe Huang, Zhen Huang, Zhenfei Huang, Zheng Huang, Zheng-Xiang Huang, Zhengwei Huang, Zhengxian Huang, Zhengxiang Huang, Zhengyang Huang, Zhenlin Huang, Zhenrui Huang, Zhenyao Huang, Zhenyi Huang, Zhi Huang, Zhi-Ming Huang, Zhi-Qiang Huang, Zhi-Xin Huang, Zhi-xiang Huang, Zhican Huang, Zhicong Huang, Zhifang Huang, Zhifeng Huang, Zhigang Huang, Zhihong Huang, Zhilin Huang, Zhilong Huang, Zhipeng Huang, Zhiping Huang, Zhiqi Huang, Zhiqiang Huang, Zhiqin Huang, Zhiqing Huang, Zhitong Huang, Zhiwei Huang, Zhixiang Huang, Zhiying Huang, Zhiyong Huang, Zhiyu Huang, Zhongbin Huang, Zhongcheng Huang, Zhongfeng Huang, Zhonglu Huang, Zhouyang Huang, Zi-Xin Huang, Zi-Ye Huang, Zicheng Huang, Zichong Huang, Zihan Huang, Zihao Huang, Ziheng Huang, Ziling Huang, Zini Huang, Zirui Huang, Zizhan Huang, Zongjian Huang, Zongliang Huang, Zunnan Huang, Zuotian Huang, Zuxian Huang, Zuyi Huang
articles
Zhen Wang, Ziheng Liu, Xing Chen +7 more · 2019 · Nature communications · Nature · added 2026-04-24
HECT E3 ligases control the degradation and functioning of numerous oncogenic/tumor-suppressive factors and signaling proteins, and their activities must be tightly regulated to prevent cancers and ot Show more
HECT E3 ligases control the degradation and functioning of numerous oncogenic/tumor-suppressive factors and signaling proteins, and their activities must be tightly regulated to prevent cancers and other diseases. Here we show that the Nedd4 family HECT E3 WWP1 adopts an autoinhibited state, in which its multiple WW domains sequester HECT using a multi-lock mechanism. Removing WW2 or WW34 led to a partial activation of WWP1. The structure of fully inhibited WWP1 reveals that many WWP1 mutations identified in cancer patients result in a partially active state with increased E3 ligase activity, and the WWP1 mutants likely promote cell migration by enhancement of ∆Np63α degradation. We further demonstrate that WWP2 and Itch utilize a highly similar multi-lock autoinhibition mechanism as that utilized by WWP1, whereas Nedd4/4 L and Smurf2 utilize a slightly variant version. Overall, these results reveal versatile autoinhibitory mechanisms that fine-tune the ligase activities of the HECT family enzymes. Show less
no PDF DOI: 10.1038/s41467-019-11224-7
WWP2
Rong Jiang, Zewei Zhou, Yan Liao +7 more · 2019 · Toxicology letters · Elsevier · added 2026-04-24
The epithelial to mesenchymal transition (EMT) contributes to fibrosis during silicosis. Zinc finger CCCH-type containing 4 protein (ZC3H4) is a novel CCCH-type zinc finger protein that activates infl Show more
The epithelial to mesenchymal transition (EMT) contributes to fibrosis during silicosis. Zinc finger CCCH-type containing 4 protein (ZC3H4) is a novel CCCH-type zinc finger protein that activates inflammation in pulmonary macrophages during silicosis. However, whether ZC3H4 is involved in EMT during silicosis remains unclear. In this study, we investigated the circular ZC3H4 (circZC3H4) RNA/microRNA-212 (miR-212) axis as the upstream molecular mechanism regulating ZC3H4 expression and the downstream mechanism by which ZC3H4 regulates EMT as well as its accompanying migratory characteristics. The protein levels were assessed via Western blotting and immunofluorescence staining. Scratch assays were used to analyze the increased mobility induced by silica. The CRISPR/Cas9 system and small interfering RNAs (siRNAs) were employed to analyze the regulatory mechanisms of ZC3H4 in EMT and migration changes. Specific knockdown of ZC3H4 blocked EMT and migration induced by silicon dioxide (SiO ZC3H4 may act as a novel regulator in the progression of SiO Show less
no PDF DOI: 10.1016/j.toxlet.2019.02.014
ZC3H4
Valérie Turcot, Yingchang Lu, Heather M Highland +408 more · 2018 · Nature genetics · Nature · added 2026-04-24
Valérie Turcot, Yingchang Lu, Heather M Highland, Claudia Schurmann, Anne E Justice, Rebecca S Fine, Jonathan P Bradfield, Tõnu Esko, Ayush Giri, Mariaelisa Graff, Xiuqing Guo, Audrey E Hendricks, Tugce Karaderi, Adelheid Lempradl, Adam E Locke, Anubha Mahajan, Eirini Marouli, Suthesh Sivapalaratnam, Kristin L Young, Tamuno Alfred, Mary F Feitosa, Nicholas G D Masca, Alisa K Manning, Carolina Medina-Gomez, Poorva Mudgal, Maggie C Y Ng, Alex P Reiner, Sailaja Vedantam, Sara M Willems, Thomas W Winkler, Gonçalo Abecasis, Katja K Aben, Dewan S Alam, Sameer E Alharthi, Matthew Allison, Philippe Amouyel, Folkert W Asselbergs, Paul L Auer, Beverley Balkau, Lia E Bang, Inês Barroso, Lisa Bastarache, Marianne Benn, Sven Bergmann, Lawrence F Bielak, Matthias Blüher, Michael Boehnke, Heiner Boeing, Eric Boerwinkle, Carsten A Böger, Jette Bork-Jensen, Michiel L Bots, Erwin P Bottinger, Donald W Bowden, Ivan Brandslund, Gerome Breen, Murray H Brilliant, Linda Broer, Marco Brumat, Amber A Burt, Adam S Butterworth, Peter T Campbell, Stefania Cappellani, David J Carey, Eulalia Catamo, Mark J Caulfield, John C Chambers, Daniel I Chasman, Yii-Der I Chen, Rajiv Chowdhury, Cramer Christensen, Audrey Y Chu, Massimiliano Cocca, Francis S Collins, James P Cook, Janie Corley, Jordi Corominas Galbany, Amanda J Cox, David S Crosslin, Gabriel Cuellar-Partida, Angela D'Eustacchio, John Danesh, Gail Davies, Paul I W Bakker, Mark C H Groot, Renée Mutsert, Ian J Deary, George Dedoussis, Ellen W Demerath, Martin Heijer, Anneke I Hollander, Hester M Ruijter, Joe G Dennis, Josh C Denny, Emanuele Di Angelantonio, Fotios Drenos, Mengmeng Du, Marie-Pierre Dubé, Alison M Dunning, Douglas F Easton, Todd L Edwards, David Ellinghaus, Patrick T Ellinor, Paul Elliott, Evangelos Evangelou, Aliki-Eleni Farmaki, I Sadaf Farooqi, Jessica D Faul, Sascha Fauser, Shuang Feng, Ele Ferrannini, Jean Ferrieres, Jose C Florez, Ian Ford, Myriam Fornage, Oscar H Franco, Andre Franke, Paul W Franks, Nele Friedrich, Ruth Frikke-Schmidt, Tessel E Galesloot, Wei Gan, Ilaria Gandin, Paolo Gasparini, Jane Gibson, Vilmantas Giedraitis, Anette P Gjesing, Penny Gordon-Larsen, Mathias Gorski, Hans-Jörgen Grabe, Struan F A Grant, Niels Grarup, Helen L Griffiths, Megan L Grove, Vilmundur Gudnason, Stefan Gustafsson, Jeff Haessler, Hakon Hakonarson, Anke R Hammerschlag, Torben Hansen, Kathleen Mullan Harris, Tamara B Harris, Andrew T Hattersley, Christian T Have, Caroline Hayward, Liang He, Nancy L Heard-Costa, Andrew C Heath, Iris M Heid, Øyvind Helgeland, Jussi Hernesniemi, Alex W Hewitt, Oddgeir L Holmen, G Kees Hovingh, Joanna M M Howson, Yao Hu, Paul L Huang, Jennifer E Huffman, M Arfan Ikram, Erik Ingelsson, Anne U Jackson, Jan-Håkan Jansson, Gail P Jarvik, Gorm B Jensen, Yucheng Jia, Stefan Johansson, Marit E Jørgensen, Torben Jørgensen, J Wouter Jukema, Bratati Kahali, René S Kahn, Mika Kähönen, Pia R Kamstrup, Stavroula Kanoni, Jaakko Kaprio, Maria Karaleftheri, Sharon L R Kardia, Fredrik Karpe, Sekar Kathiresan, Frank Kee, Lambertus A Kiemeney, Eric Kim, Hidetoshi Kitajima, Pirjo Komulainen, Jaspal S Kooner, Charles Kooperberg, Tellervo Korhonen, Peter Kovacs, Helena Kuivaniemi, Zoltán Kutalik, Kari Kuulasmaa, Johanna Kuusisto, Markku Laakso, Timo A Lakka, David Lamparter, Ethan M Lange, Leslie A Lange, Claudia Langenberg, Eric B Larson, Nanette R Lee, Terho Lehtimäki, Cora E Lewis, Huaixing Li, Jin Li, Ruifang Li-Gao, Honghuang Lin, Keng-Hung Lin, Li-An Lin, Xu Lin, Lars Lind, Jaana Lindström, Allan Linneberg, Ching-Ti Liu, Dajiang J Liu, Yongmei Liu, Ken S Lo, Artitaya Lophatananon, Andrew J Lotery, Anu Loukola, Jian'an Luan, Steven A Lubitz, Leo-Pekka Lyytikäinen, Satu Männistö, Gaëlle Marenne, Angela L Mazul, Mark I McCarthy, Roberta McKean-Cowdin, Sarah E Medland, Karina Meidtner, Lili Milani, Vanisha Mistry, Paul Mitchell, Karen L Mohlke, Leena Moilanen, Marie Moitry, Grant W Montgomery, Dennis O Mook-Kanamori, Carmel Moore, Trevor A Mori, Andrew D Morris, Andrew P Morris, Martina Müller-Nurasyid, Patricia B Munroe, Mike A Nalls, Narisu Narisu, Christopher P Nelson, Matt Neville, Sune F Nielsen, Kjell Nikus, Pål R Njølstad, Børge G Nordestgaard, Dale R Nyholt, Jeffrey R O'Connel, Michelle L O'Donoghue, Loes M Olde Loohuis, Roel A Ophoff, Katharine R Owen, Chris J Packard, Sandosh Padmanabhan, Colin N A Palmer, Nicholette D Palmer, Gerard Pasterkamp, Aniruddh P Patel, Alison Pattie, Oluf Pedersen, Peggy L Peissig, Gina M Peloso, Craig E Pennell, Markus Perola, James A Perry, John R B Perry, Tune H Pers, Thomas N Person, Annette Peters, Eva R B Petersen, Patricia A Peyser, Ailith Pirie, Ozren Polasek, Tinca J Polderman, Hannu Puolijoki, Olli T Raitakari, Asif Rasheed, Rainer Rauramaa, Dermot F Reilly, Frida Renström, Myriam Rheinberger, Paul M Ridker, John D Rioux, Manuel A Rivas, David J Roberts, Neil R Robertson, Antonietta Robino, Olov Rolandsson, Igor Rudan, Katherine S Ruth, Danish Saleheen, Veikko Salomaa, Nilesh J Samani, Yadav Sapkota, Naveed Sattar, Robert E Schoen, Pamela J Schreiner, Matthias B Schulze, Robert A Scott, Marcelo P Segura-Lepe, Svati H Shah, Wayne H-H Sheu, Xueling Sim, Andrew J Slater, Kerrin S Small, Albert V Smith, Lorraine Southam, Timothy D Spector, Elizabeth K Speliotes, John M Starr, Kari Stefansson, Valgerdur Steinthorsdottir, Kathleen E Stirrups, Konstantin Strauch, Heather M Stringham, Michael Stumvoll, Liang Sun, Praveen Surendran, Amy J Swift, Hayato Tada, Katherine E Tansey, Jean-Claude Tardif, Kent D Taylor, Alexander Teumer, Deborah J Thompson, Gudmar Thorleifsson, Unnur Thorsteinsdottir, Betina H Thuesen, Anke Tönjes, Gerard Tromp, Stella Trompet, Emmanouil Tsafantakis, Jaakko Tuomilehto, Anne Tybjaerg-Hansen, Jonathan P Tyrer, Rudolf Uher, André G Uitterlinden, Matti Uusitupa, Sander W Laan, Cornelia M Duijn, Nienke Leeuwen, Jessica van Setten, Mauno Vanhala, Anette Varbo, Tibor V Varga, Rohit Varma, Digna R Velez Edwards, Sita H Vermeulen, Giovanni Veronesi, Henrik Vestergaard, Veronique Vitart, Thomas F Vogt, Uwe Völker, Dragana Vuckovic, Lynne E Wagenknecht, Mark Walker, Lars Wallentin, Feijie Wang, Carol A Wang, Shuai Wang, Yiqin Wang, Erin B Ware, Nicholas J Wareham, Helen R Warren, Dawn M Waterworth, Jennifer Wessel, Harvey D White, Cristen J Willer, James G Wilson, Daniel R Witte, Andrew R Wood, Ying Wu, Hanieh Yaghootkar, Jie Yao, Pang Yao, Laura M Yerges-Armstrong, Robin Young, Eleftheria Zeggini, Xiaowei Zhan, Weihua Zhang, Jing Hua Zhao, Wei Zhao, Wei Zhou, Krina T Zondervan, CHD Exome+ Consortium, EPIC-CVD Consortium, ExomeBP Consortium, Global Lipids Genetic Consortium, GoT2D Genes Consortium, EPIC InterAct Consortium, INTERVAL Study, ReproGen Consortium, T2D-Genes Consortium, MAGIC Investigators, Understanding Society Scientific Group, Jerome I Rotter, John A Pospisilik, Fernando Rivadeneira, Ingrid B Borecki, Panos Deloukas, Timothy M Frayling, Guillaume Lettre, Kari E North, Cecilia M Lindgren, Joel N Hirschhorn, Ruth J F Loos Show less
Genome-wide association studies (GWAS) have identified >250 loci for body mass index (BMI), implicating pathways related to neuronal biology. Most GWAS loci represent clusters of common, noncoding var Show more
Genome-wide association studies (GWAS) have identified >250 loci for body mass index (BMI), implicating pathways related to neuronal biology. Most GWAS loci represent clusters of common, noncoding variants from which pinpointing causal genes remains challenging. Here we combined data from 718,734 individuals to discover rare and low-frequency (minor allele frequency (MAF) < 5%) coding variants associated with BMI. We identified 14 coding variants in 13 genes, of which 8 variants were in genes (ZBTB7B, ACHE, RAPGEF3, RAB21, ZFHX3, ENTPD6, ZFR2 and ZNF169) newly implicated in human obesity, 2 variants were in genes (MC4R and KSR2) previously observed to be mutated in extreme obesity and 2 variants were in GIPR. The effect sizes of rare variants are ~10 times larger than those of common variants, with the largest effect observed in carriers of an MC4R mutation introducing a stop codon (p.Tyr35Ter, MAF = 0.01%), who weighed ~7 kg more than non-carriers. Pathway analyses based on the variants associated with BMI confirm enrichment of neuronal genes and provide new evidence for adipocyte and energy expenditure biology, widening the potential of genetically supported therapeutic targets in obesity. Show less
📄 PDF DOI: 10.1038/s41588-017-0011-x
GIPR
Yuhuan Meng, Ying Cui, Wenlu Zhang +4 more · 2018 · Frontiers in genetics · Frontiers · added 2026-04-24
The Goto Kakizaki (GK) rats which can spontaneously develop type 2 diabetes (T2D), are generated by repeated inbreeding of Wistar rats with glucose intolerance. The glucose intolerance in GK rat is ma Show more
The Goto Kakizaki (GK) rats which can spontaneously develop type 2 diabetes (T2D), are generated by repeated inbreeding of Wistar rats with glucose intolerance. The glucose intolerance in GK rat is mainly attributed to the impairment in glucose-stimulated insulin secretion (GSIS). In addition, GK rat display a decrease in beta cell mass, and a change in insulin action. However, the genetic mechanism of these features remain unclear. In the present study, we analyzed the population variants of GK rats and control Wistar rats by whole genome sequencing and identified 1,839 and 1,333 specific amino acid changed (SAAC) genes in GK and Wistar rats, respectively. We also detected the putative artificial selective sweeps (PASS) regions in GK rat which were enriched with GK fixed variants and were under selected in the initial diabetic-driven derivation by homogeneity test with the fixed and polymorphic sites between GK and Wistar populations. Finally, we integrated the SAAC genes, PASS region genes and differentially expressed genes in GK pancreatic beta cells to reveal the genetic mechanism of the impairment in GSIS, a decrease in beta cell mass, and a change in insulin action in GK rat. The results showed that Show less
📄 PDF DOI: 10.3389/fgene.2018.00724
ADCY3
Sheng Shi, Jiacheng Sun, Qingyou Meng +7 more · 2018 · Journal of thoracic disease · added 2026-04-24
Bone marrow-derived mesenchymal stem cells (BMSCs) have been proved to be capable of differentiating into endothelial cells (ECs), however, the differentiation efficiency is rather low. Sonic hedgehog Show more
Bone marrow-derived mesenchymal stem cells (BMSCs) have been proved to be capable of differentiating into endothelial cells (ECs), however, the differentiation efficiency is rather low. Sonic hedgehog (Shh), an important factor in vascular development and postnatal angiogenesis, exerted promotional effect on new vessel formation in the ischemic animal models. Therefore, the current study aims to investigate whether Shh could induce the endothelial differentiation of BMSCs both The current study over-expressed Shh in BMSCs by lentivirus transduction. Reverse-transcription quantitative polymerase chain reaction (RT-qPCR) analysis was performed to determine the angiogenic factors in both control BMSCs and Shh over-expressed BMSCs. Immunocytochemistry was also conducted to examine the EC markers. Angiogenesis was determined by Shh expression was increased by about 3,000-fold and 5,000-fold at 3 days-transfection and 7 days-transfection, respectively. Patched 1 (Ptch1), the receptor for Shh, had a two-fold increase after transduction. The angiogenic factors such as hepatocyte growth factor (HGF), angiopoietin-1 (Ang-1), insulin-like growth factor 1 (IGF1) and vascular endothelial growth factor A (VEGF-A) had at least a 1.5-fold increase after transduction. Expression of EC-lineage markers, CD31 and VE-cadherin, on Shh-overexpressed BMSCs were increasingly detected by immunocytostaining. Angiogenesis of BMSCs could be efficiently induced by Shh overexpression in the This study demonstrated that Shh could promote endothelial differentiation of BMSCs via VEGF-D. Show less
no PDF DOI: 10.21037/jtd.2018.09.50
ANGPTL4
Qian Yang, Rui-Xing Yin, Xiao-Li Cao +3 more · 2018 · Nutrition & metabolism · BioMed Central · added 2026-04-24
This study aimed to assess the association between the angiopoietin-like protein 4 gene ( Genotypes of the The rs2967605 CT/TT genotypes were associated with a decreased risk of CAD (adjusted OR = 0.6 Show more
This study aimed to assess the association between the angiopoietin-like protein 4 gene ( Genotypes of the The rs2967605 CT/TT genotypes were associated with a decreased risk of CAD (adjusted OR = 0.68, 95% CI = 0.47-0.99, The observed associations suggest that the Show less
📄 PDF DOI: 10.1186/s12986-018-0308-5
ANGPTL4
Derek Klarin, Scott M Damrauer, Kelly Cho +46 more · 2018 · Nature genetics · Nature · added 2026-04-24
The Million Veteran Program (MVP) was established in 2011 as a national research initiative to determine how genetic variation influences the health of US military veterans. Here we genotyped 312,571 Show more
The Million Veteran Program (MVP) was established in 2011 as a national research initiative to determine how genetic variation influences the health of US military veterans. Here we genotyped 312,571 MVP participants using a custom biobank array and linked the genetic data to laboratory and clinical phenotypes extracted from electronic health records covering a median of 10.0 years of follow-up. Among 297,626 veterans with at least one blood lipid measurement, including 57,332 black and 24,743 Hispanic participants, we tested up to around 32 million variants for association with lipid levels and identified 118 novel genome-wide significant loci after meta-analysis with data from the Global Lipids Genetics Consortium (total n > 600,000). Through a focus on mutations predicted to result in a loss of gene function and a phenome-wide association study, we propose novel indications for pharmaceutical inhibitors targeting PCSK9 (abdominal aortic aneurysm), ANGPTL4 (type 2 diabetes) and PDE3B (triglycerides and coronary disease). Show less
📄 PDF DOI: 10.1038/s41588-018-0222-9
ANGPTL4
S Huang, M Wang, M U Rehman +4 more · 2018 · Journal of comparative pathology · Elsevier · added 2026-04-24
The aim of this study was to investigate the role and expression of a novel angiogenic factor (angiopoietin-like 4, ANGPTL4) in tibial growth plates of broiler chickens exposed to high-altitude hypoxi Show more
The aim of this study was to investigate the role and expression of a novel angiogenic factor (angiopoietin-like 4, ANGPTL4) in tibial growth plates of broiler chickens exposed to high-altitude hypoxia. One-day-old healthy broiler chickens (n = 120) were transported from lowland to a high-altitude hypoxic region (nearly 3,000 m above sea level) and were reared under hypoxic- (natural lower oxygen content) and normoxic conditions (nearly 21% oxygen content) for 14 days. The effect of hypoxia on angiogenesis in the tibial growth plates and hypoxia-inducible factor (HIF)-1α and ANGPTL4 expressions were determined by histological examination, quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), western blot and enzyme-linked immunosorbent assay (ELISA) techniques. The increase in vascular distribution to the hypertrophic chondrocyte zone of tibial growth plates contributed to promoting growth and development of the tibia under hypoxic conditions, which was highly correlated with the upregulation of ANGPTL4 at both the mRNA and protein levels together with activation of HIF-1α under hypoxic conditions. These findings demonstrate that angiogenic factor ANGPTL4 upregulation is involved in tibial growth plate angiogenesis to promote the development of the tibia in broiler chickens under hypoxic conditions. They also suggest that ANGPTL4 may serve as a new molecular therapeutic target for ameliorating tibial dyschondroplasia chicken bone vascularization. Show less
no PDF DOI: 10.1016/j.jcpa.2018.04.007
ANGPTL4
Jin-Wu Chen, Ying-Jia Luo, Zheng-Fei Yang +2 more · 2018 · Oncology reports · added 2026-04-24
Human gastric cancer (GC) is the second most common cause of cancer-related deaths worldwide and is one of the most common metastatic cancers. Tumor proliferation, apoptosis, metastasis and invasion a Show more
Human gastric cancer (GC) is the second most common cause of cancer-related deaths worldwide and is one of the most common metastatic cancers. Tumor proliferation, apoptosis, metastasis and invasion are important predictors of the invasiveness of GC and are key factors in cancer-induced death. Angiopoietin-like 4 (ANGPTL4) is a secreted protein that belongs to the angiopoietin (ANGPTL) family and is involved in the regulation of cancer metastasis. However, whether ANGPTL4 plays a role in the progression of GC remain unclear. In the present study, immunoreactivity of ANGPTL4 demonstrated that ANGPTL4 expression was upregulated in GC tissues with the development of GC. The siRNA targeting ANGPTL4 effectively knocked down ANGPTL4 in the SNU‑1 and BGC823 cell lines at the mRNA and protein levels. Following ANGPTL4 downregulation, the proliferation and invasion abilities of GC cell lines were suppressed as determined by MTT and Transwell assays, and cell apoptosis level and sensitivity to cisplatin were increased as determined by flow cytometry and MTT assay. In conclusion, these findings suggest that ANGPTL4 may be a new potential therapeutic target for GC. Show less
no PDF DOI: 10.3892/or.2018.6253
ANGPTL4
Lan Zhou, Yufang Huang, Hui Xie +1 more · 2018 · Molecular medicine reports · added 2026-04-24
Denervated-dependent skeletal muscle atrophy (DSMA) is a disorder caused by the peripheral neuro‑disconnection of skeletal muscle. The current study aimed to investigate the molecular mechanism and po Show more
Denervated-dependent skeletal muscle atrophy (DSMA) is a disorder caused by the peripheral neuro‑disconnection of skeletal muscle. The current study aimed to investigate the molecular mechanism and potential therapeutic strategies for the DSMA. A DSMA rat model was established. A lentiviral vector expressing small interfering RNA (siRNA) targeting angiopoietin‑like protein 4 (ANGPTL4) was generated and injected into the rats that were also treated with Buyang Huanwu Tang (BYHWT). Reverse transcription‑quantitative polymerase chain reaction was performed to examine ANGPTL4 mRNA expression in anterior cervical muscle samples. Western blot assay was used to evaluate ANGPTL4, nuclear factor‑κB (NF‑κB) and muscle RING‑finger protein‑1 (MURF1) expression. The ultrastructure of muscle tissues was viewed using transmission electron microscopy. The cell apoptosis in muscle tissues was detected using the terminal deoxynucleotidyl transferase dUTP nick end labeling. The results indicated that BYHWT treatment increased ANGPTL4 mRNA and protein levels in muscle tissues. The suppression of ANGPTL4 using siRNA significantly increased inflammatory cells compared with the control siRNA group. BYHWT protected the ultrastructure muscle tissues and inhibited cell apoptosis in the DSMA model. The protective effect of BYHWT protected may be mediated by increased expression of NF‑κB p65 and MURF1. In conclusion, BYHWT may improve denervation‑dependent muscle atrophy by increasing ANGPTL4 expression, involving NF‑κB and MURF1 signaling. Show less
📄 PDF DOI: 10.3892/mmr.2017.8306
ANGPTL4
Yetao Xu, Yifan Lian, Yuanyuan Zhang +6 more · 2018 · Journal of cellular and molecular medicine · Blackwell Publishing · added 2026-04-24
Despite progress in diagnostics and treatment for preeclampsia, it remains the foremost cause of maternal and foetal perinatal morbidity and mortality worldwide. Over recent years, various lines of ev Show more
Despite progress in diagnostics and treatment for preeclampsia, it remains the foremost cause of maternal and foetal perinatal morbidity and mortality worldwide. Over recent years, various lines of evidence have emphasized long non-coding RNAs (lncRNAs) which function as an innovative regulator of biological behaviour, as exemplified by proliferation, apoptosis and metastasis. However, the role of lncRNAs has not been well described in preeclampsia. Here, we identified a lncRNA, PVT1, whose expression was down-regulated in qRT-PCR analyses in severe preeclampsia. The effects of PVT1 on development were studied after suppression and overexpression of PVT1 in HTR-8/SVneo and JEG3 cells. PVT1 knockdown notably inhibited cell proliferation and stimulated cell cycle accumulation and apoptosis. Exogenous PVT1 significantly increased cell proliferation. Based on analysis of RNAseq data, we found that PVT1 could affect the expression of numerous genes, and then investigated the function and regulatory mechanism of PVT1 in trophoblast cells. Further mechanistic analyses implied that the action of PVT1 is moderately attributable to its repression of ANGPTL4 via association with the epigenetic repressor Ezh2. Altogether, our study suggests that PVT1 could play an essential role in preeclampsia progression and probably acts as a latent therapeutic marker; thus, it might be a useful prognostic marker when evaluating new therapies for patients with preeclampsia. Show less
📄 PDF DOI: 10.1111/jcmm.13405
ANGPTL4
Qiong Ye, Guo-Ping Tian, Hai-Peng Cheng +17 more · 2018 · Journal of atherosclerosis and thrombosis · added 2026-04-24
Atherosclerosis is the most common cause of cardiovascular disease, such as myocardial infarction and stroke. Previous study revealed that microRNA (miR)-134 promotes lipid accumulation and proinflamm Show more
Atherosclerosis is the most common cause of cardiovascular disease, such as myocardial infarction and stroke. Previous study revealed that microRNA (miR)-134 promotes lipid accumulation and proinflammatory cytokine secretion through angiopoietin-like 4 (ANGPTL4)/lipid lipoprotein (LPL) signaling in THP-1 macrophages. ApoE KO male mice on a C57BL/6 background were fed a high-fat/high-cholesterol Western diet, from 8 to 16 weeks of age. Mice were divided into four groups, and received a tail vein injection of miR-134 agomir, miR-134 antagomir, or one of the corresponding controls, respectively, once every 2 weeks after starting the Western diet. After 8 weeks we measured aortic atherosclerosis, LPL Activity, mRNA and protein levels of ANGPTL4 and LPL, LPL/ low-density lipoprotein receptor related protein 1 Complex Formation, proinflammatory cytokine secretion and lipid levels. Despite this finding, the influence of miR-134 on atherosclerosis in vivo remains to be determined. Using the well-characterized mouse atherosclerosis model of apolipoprotein E knockout, we found that systemic delivery of miR-134 agomir markedly enhanced the atherosclerotic lesion size, together with a significant increase in proinflammatory cytokine secretion and peritoneal macrophages lipid contents. Moreover, overexpression of miR-134 decreased ANGPTL4 expression but increased LPL expression and activity in both aortic tissues and peritoneal macrophages, which was accompanied by increased formation of LPL/low-density lipoprotein receptor-related protein 1 complexes in peritoneal macrophages. However, an opposite effect was observed in response to miR-134 antagomir. These findings suggest that miR-134 accelerates atherogenesis by promoting lipid accumulation and proinflammatory cytokine secretion via the ANGPTL4/LPL pathway. Therefore, targeting miR-134 may offer a promising strategy for the prevention and treatment of atherosclerotic cardiovascular disease. Show less
📄 PDF DOI: 10.5551/jat.40212
ANGPTL4
Chih-Yuan Fang, Mien-Cheng Chen, Tzu-Hao Chang +10 more · 2018 · International journal of molecular sciences · MDPI · added 2026-04-24
Lipid expression is increased in the atrial myocytes of mitral regurgitation (MR) patients. This study aimed to investigate key regulatory genes and mechanisms of atrial lipotoxic myopathy in MR. The Show more
Lipid expression is increased in the atrial myocytes of mitral regurgitation (MR) patients. This study aimed to investigate key regulatory genes and mechanisms of atrial lipotoxic myopathy in MR. The HL-1 atrial myocytes were subjected to uniaxial cyclic stretching for eight hours. Fatty acid metabolism, lipoprotein signaling, and cholesterol metabolism were analyzed by PCR assay (168 genes). The stretched myocytes had significantly larger cell size and higher lipid expression than non-stretched myocytes (all The Show less
📄 PDF DOI: 10.3390/ijms19124094
APOA4
Quanxi Wang, Mengxi Liu, Lihui Xu +2 more · 2018 · Avian pathology : journal of the W.V.P.A · Taylor & Francis · added 2026-04-24
The aim of this work was to clarify the molecular mechanism underlying the fatty degeneration of livers infected with Muscovy duck reovirus (MDRV), which produces obvious white necrotic foci in the li Show more
The aim of this work was to clarify the molecular mechanism underlying the fatty degeneration of livers infected with Muscovy duck reovirus (MDRV), which produces obvious white necrotic foci in the liver. Transcriptome data for MDRV-infected Muscovy duck livers and control livers were sequenced, assembled, and annotated with Illumina ABC: ATP binding cassette transport; ACADVL: acyl-CoA dehydrogenase, very long chain; ACAT: mitochondrial-like acetyl-CoA acetyltransferase A; ACAT2: acetyl-CoA acyltransferase 2; ACNAT2: acyl-coenzyme A amino acid N-acyltransferase 2-like; ACOT1: acyl-CoA thioesterase 1; ACOT7: acyl-CoA thioesterase 7; ACOX1: acyl-CoA oxidase 1, palmitoyl; ACSBG2: acyl-CoA synthetase bubblegum family member 2; ACSL1: acyl-CoA synthetase long-chain family member 1; ADH1: alcohol dehydrogenase 1; APOA4: apolipoprotein A-IV; ARV: avian reovirus; cDNA: complementary deoxyribonucleic acid; COG: Clusters of Orthologous Groups; DEG: differentially expressed gene; DGAT: diacylgycerol acyltransferase; DNA: deoxyribonucleic acid; ECI2: enoyl-CoA delta isomerase 2; EHHADH: enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase; FDR: false discovery rate; GCDH: Pseudopodoces humilis glutaryl-CoA dehydrogenase; GO: Gene Ontology; HADHA: hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), alpha subunit; I-FABP: intestinal fatty acid binding protein; KEGG: Kyoto Encyclopedia of Genes and Genomes; L-FABP: liver fatty acid binding protein; MDRV: Muscovy duck reovirus; MOI: multiplicity of infection; NPC1L1: Niemann-Pick C1-like 1; qPCR: real-time quantitative polymerase chain reaction; RNA: ribonucleic acid; RNase: ribonuclease; RNA-seq: RNA sequencing technology; RPKM: reads per kilobase per million mapped reads; SR-B1: scavenger receptor class b type 1. Show less
no PDF DOI: 10.1080/03079457.2017.1380294
APOA4
Xiangyun Liu, Guoyuan Huang, Zhanbin Niu +2 more · 2018 · Experimental gerontology · Elsevier · added 2026-04-24
The genetic component of dyslipidemia has been studied in adults but little in older population. It is remains unknown regarding influence and interaction of APOA5 gene single nucleotide polymorphism Show more
The genetic component of dyslipidemia has been studied in adults but little in older population. It is remains unknown regarding influence and interaction of APOA5 gene single nucleotide polymorphism (SNP) and habitual aerobic exercise (HAE) on changes of blood lipids and lipoprotein phenotypes in older Chinese adults. Four-hundred-twenty-three old Chinese individuals with HAE were divided into hyperlipidemia and normal groups. We genotyped polymorphic loci using matrix assisted laser desorption ionization time of flight mass spectrometry detection technology (MALDI-TOF). HAE level was assessed by International Physical Activity Questionnaire (IPAQ) scale. For three genotypes of rs662799 site, the AG + GG gene carriers presented higher risk of hyperlipidemia compared to the AA carriers, with the ratio of 1.676 (P = .018, 95% CI: 1.092-2.571) for the AG and 1.812 (P = .002, 95% CI: 1.247-2.632) for the GG, respectively. The rs662799 G allele was significantly associated with lower HDL-C but higher TG levels. In relation to different HAE levels, less interaction was observed between the AA carriers and different HAE levels on corresponding lipids changes. The AG + GG carriers with higher HAE levels had significantly lower TG responses compared to those with lower HAE levels (1.45 ± 0.74 mmol/L vs. 1.86 ± 1.15 mmol/L). Excess risk for low HDL-C and hyperlipidemia was associated with rs662799 genotype alleles of APOA5 SNPs in older Chinese adults. Interaction of gene-HAE and HAE levels may induce different responses of blood lipids and lipoprotein phenotypes. HAE levels have less influence on TG changes in the AA carriers; however, high HAE levels appeared to greatly impact TG responses in the AG + GG carriers. Show less
no PDF DOI: 10.1016/j.exger.2018.05.007
APOA5
Dandan Zhong, Zhengwei Xie, Boyue Huang +6 more · 2018 · Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · added 2026-04-24
Non-alcoholic fatty liver disease (NAFLD) encompasses a series of pathologic changes ranging from steatosis to steatohepatitis, which may progress to cirrhosis and hepatocellular carcinoma. The purpos Show more
Non-alcoholic fatty liver disease (NAFLD) encompasses a series of pathologic changes ranging from steatosis to steatohepatitis, which may progress to cirrhosis and hepatocellular carcinoma. The purpose of this study was to determine whether ganoderma lucidum polysaccharide peptide (GLPP) has therapeutic effect on NAFLD. Ob/ ob mouse model and ApoC3 transgenic mouse model were used for exploring the effect of GLPP on NAFLD. Key metabolic pathways and enzymes were identified by metabolomics combining with KEGG and PIUmet analyses and key enzymes were detected by Western blot. Hepatosteatosis models of HepG2 cells and primary hepatocytes were used to further confirm the therapeutic effect of GLPP on NAFLD. GLPP administrated for a month alleviated hepatosteatosis, dyslipidemia, liver dysfunction and liver insulin resistance. Pathways of glycerophospholipid metabolism, fatty acid metabolism and primary bile acid biosynthesis were involved in the therapeutic effect of GLPP on NAFLD. Detection of key enzymes revealed that GLPP reversed low expression of CYP7A1, CYP8B1, FXR, SHP and high expression of FGFR4 in ob/ob mice and ApoC3 mice. Besides, GLPP inhibited fatty acid synthesis by reducing the expression of SREBP1c, FAS and ACC via a FXR-SHP dependent mechanism. Additionally, GLPP reduced the accumulation of lipid droplets and the content of TG in HepG2 cells and primary hepatocytes induced by oleic acid and palmitic acid. GLPP significantly improves NAFLD via regulating bile acid synthesis dependent on FXR-SHP/FGF pathway, which finally inhibits fatty acid synthesis, indicating that GLPP might be developed as a therapeutic drug for NAFLD. Show less
no PDF DOI: 10.1159/000493297
APOC3
Qiu Peng, Ling Chen, Wei Wu +9 more · 2018 · Cell death & disease · Nature · added 2026-04-24
The erythropoietin-producing hepatoma (EPH) receptor A2 (EphA2) belongs to the Eph family of receptor tyrosine kinases. EphA2 is highly correlated with the formation of many solid tumors and has been Show more
The erythropoietin-producing hepatoma (EPH) receptor A2 (EphA2) belongs to the Eph family of receptor tyrosine kinases. EphA2 is highly correlated with the formation of many solid tumors and has been linked to the dysregulation of signaling pathways that promote tumor cell proliferation, migration, and invasion as well as angiogenesis. Deregulation of Wnt signaling is implicated in many forms of human disease including gastric cancer. We previously reported that EphA2 promotes the epithelial-mesenchymal transition through Wnt/β-catenin signaling in gastric cancer. Herein, we present a novel mechanism by which EphA2 regulates Wnt/β-catenin signaling. EphA2 acts as a receptor for Wnt ligands and recruits Axin1 to the plasma membrane by directly binding Dvl2. The EphA2-Dvl2/Axin1 interaction was enhanced by Wnt3a treatment, suggesting that EphA2 acts as a functional receptor for the Wnt/β-catenin pathway and plays a vital role in downstream signaling. We showed that Dvl2 mediates the EphA2-Axin1 interaction by binding to the tyrosine kinase domain of EphA2. We propose that EphA2/Dvl2/Axin1 forms a complex that destabilizes the β-catenin destruction complex and allows β-catenin to translocate to the nucleus and initiate the transcription of c-MYC, the primary Wnt signaling target gene. Intriguingly, c-MYC could bind directly to the EphA2 and Wnt1 promoter to enhance their transcription. The entire process formed an EphA2-mediated feed-forward loop. A small molecular inhibitor of EphA2 potently inhibited the proliferation of gastric cancer in vitro and in vivo, including gastric cancer patient-derived xenografts. Thus, our data identify EphA2 as an excellent candidate for gastric cancer therapy. Show less
📄 PDF DOI: 10.1038/s41419-018-1164-y
AXIN1
Xiong-Bai Zhu, Wen-Jun Lin, Chen Lv +4 more · 2018 · Journal of cellular biochemistry · Wiley · added 2026-04-24
This study aims to explore the effects of miR-539 on osteoblast proliferation and differentiation and osteoclast apoptosis in a rat model of osteoporosis, and its mechanism involving the regulation of Show more
This study aims to explore the effects of miR-539 on osteoblast proliferation and differentiation and osteoclast apoptosis in a rat model of osteoporosis, and its mechanism involving the regulation of the AXIN1-mediated wingless-Int (Wnt) signaling pathway. A rat model of osteoporosis was successfully established by ovariectomy. With osteoblasts and osteoclasts of rats not receiving ovariectomy in the sham group as control, those of osteoporotic rats were treated with miR-539 inhibitor, miR-539 mimic, and AXIN1 shRNA. The expression of miR-53, AXIN1, the Wnt pathway related-genes, apoptosis related-genes, and osteogenic markers were measured by RT-qPCR and Western blot analysis, respectively. Alkaline phosphatase (ALP) activity in osteoblast and tartrate-resistant acid phosphatase (TRAP) activity in osteoclasts were determined after cell transfection. Osteoblast and osteoclast viability was assayed by CCK-8 assay. Cell cycle and apoptosis of osteoblasts and osteoclasts were detected by flow cytometry. Lastly, alizarin red S staining was used to detect mineralized nodules of osteoblasts. Firstly, we determined that miR-539 was down-regulated in osteoblast and osteoclast of osteoporotic rats and AXIN1 was negatively regulated by miR-539. Additionally, overexpression of miR-539 increased the expressions of β-catenin, LEF1, c-myc, cyclin D1, RUNX2, BGP, BMP-2 in osteoblast as well as β-catenin, RhoA, caspase-3, and Bcl-2 in osteoclasts. Finally, overexpression of miR-539 elevated ALP activity, proliferation, and mineralized nodules in osteoblast and osteoclast apoptosis, with reduced TRAP activity in osteoclasts. Our results demonstrate that miR-539 promotes osteoblast proliferation and differentiation as well as osteoclast apoptosis through the AXIN1-dependent Wnt signaling pathway in osteoporotic rats. Show less
no PDF DOI: 10.1002/jcb.26910
AXIN1
Gang Ning, Yan-Lin Huang, Li-Min Zhen +9 more · 2018 · Aging · Impact Journals · added 2026-04-24
Chromobox (CBX) proteins are important components of epigenetic regulation complexes known to play key roles in hepatocellular carcinoma (HCC). Little is known about the function of distinct CBXs in H Show more
Chromobox (CBX) proteins are important components of epigenetic regulation complexes known to play key roles in hepatocellular carcinoma (HCC). Little is known about the function of distinct CBXs in HCC. To address this issue, the study investigated the roles of CBXs in the prognosis of HCC using ONCOMINE, UALCAN, Human Protein Atlas, Kaplan-Meier Plotter, Show less
📄 PDF DOI: 10.18632/aging.101658
CBX1
Rui Wang, Mei Huang, Linting Li +5 more · 2018 · Analytical chemistry · ACS Publications · added 2026-04-24
A basic but critical step in targeted proteomics by mass spectrometry is the separation of the targeted proteins from the complex mixture of the whole proteome by affinity purification. The bait prote Show more
A basic but critical step in targeted proteomics by mass spectrometry is the separation of the targeted proteins from the complex mixture of the whole proteome by affinity purification. The bait protein is usually immobilized on the surface of a solid support to enable affinity-based purification of the targeted proteome. Here, we developed a site-specific covalent immobilization of the bait protein through affinity-guided covalent coupling (AGCC) of a single cysteine residue of an SH2 domain (utilized as an affinity tag for the protein target) with an engineered ligand peptide. Site-specific covalent immobilization of a methyllysine-binding protein HP1β chromodomain on the agarose resin was used to purify the methyllysine proteome from the whole-protein mixture. This new bait immobilization led to a notably low background in the affinity purification step, markedly outperforming the conventional (His) Show less
no PDF DOI: 10.1021/acs.analchem.8b02796
CBX1
Gaojun Cai, Ganwei Shi, Zhiying Huang · 2018 · Medicine · added 2026-04-24
Numerous studies have shown a relationship between cholesteryl ester transfer protein (CETP) polymorphism in the synthesis of high-density lipoprotein cholesterol (HDL-C) and the coronary artery disea Show more
Numerous studies have shown a relationship between cholesteryl ester transfer protein (CETP) polymorphism in the synthesis of high-density lipoprotein cholesterol (HDL-C) and the coronary artery disease (CAD) susceptibility, but the results have remained inconsistent. In addition, there was no study exploring the relationship between CETP polymorphisms and atherogenic index of plasma (AIP) levels.We conducted a case-control study to evaluate the relationship between CETP rs708272 polymorphism and CAD risk and lipid levels in Chinese Han population. 556 CAD patients and 414 controls undergoing coronary angiography were consecutively enrolled in the hospital-based study. Polymerase chain reaction-ligase detection reaction (PCR-LDR) method was used to detect the different genotypes at rs708272.No significant association between CETP rs708272 polymorphism and CAD risk was observed in different genetic models. In the whole population, participants with TT genotype had higher HDL-C levels (1.17 ± 0.31 mmol/L vs 1.09 ± 0.29 mmol/L, P = .001) and lower AIP levels (0.08 ± 0.35 vs 0.16 ± 0.31, P = .004) compared to those with CC genotype, after adjusting for age, gender, smoking, essential hypertension (EH), and DM. The T allele carriers had higher HDL-C levels than the T allele non-carriers (1.13 ± 0.29 mmol/L vs 1.09 ± 0.29 mmol/L, P = .023). Furthermore, subgroup analyses based on gender were carried out. In males, the results showed that participants with TT genotype had significant higher HDL-C levels and lower AIP levels compared with CC genotype (P <.05). In addition, males with CT+TT genotypes had higher HDL-C levels and lower AIP levels than those with CC genotypes (HDL-C: CT+TT 1.11 ± 0.31vs CC 1.06 ± 0.30 mmol/L, P = .041; AIP: CT+TT 0.12 ± 0.32vs CC 0.16 ± 0.31, P = .034, respectively). However, there were no significant associations between lipid levels and CETP rs708272 polymorphism in females, after adjusting for confounders.CETP rs708272 polymorphism has a gender-specific effect on lipid and AIP levels but not on the risk of CAD. Show less
📄 PDF DOI: 10.1097/MD.0000000000013514
CETP
Nan Wu, Guili Liu, Yi Huang +5 more · 2018 · Anatolian journal of cardiology · added 2026-04-24
Blood lipids are well-known risk factors for coronary heart disease (CHD). The aim of this study was to explore the association between 17 lipid-related gene polymorphisms and CHD. The current study e Show more
Blood lipids are well-known risk factors for coronary heart disease (CHD). The aim of this study was to explore the association between 17 lipid-related gene polymorphisms and CHD. The current study examined with 784 CHD cases and 739 non-CHD controls. Genotyping was performed on the MassARRAY iPLEX® assay platform. Our analyses revealed a significant association of APOE rs7259620 with CHD (genotype: χ2=6.353, df=2, p=0.042; allele: χ2=5.05, df=1, p=0.025; recessive model: χ2=5.57, df=1, p=0.018). A further gender-based subgroup analysis revealed significant associations of APOE rs7259620 and PPAP2B rs72664392 with CHD in males (genotype: χ2=8.379, df=2, p=0.015; allele: χ2=5.190, df=1, p=0.023; recessive model: χ2=19.3, df=1, p<0.0001) and females (genotype: χ2=9.878, df=2, p=0.007), respectively. Subsequent breakdown analysis by age showed that CETP rs4783961, MLXIPL rs35493868, and PON2 rs12704796 were significantly associated with CHD among individuals younger than 55 years of age (CETP rs4783961: χ2=8.966, df=1, p=0.011 by genotype; MLXIPL rs35493868: χ2=4.87, df=1, p=0.027 by allele; χ2=4.88, df=1, p=0.027 by dominant model; PON2 rs12704796: χ2=6.511, df=2, p=0.039 by genotype; χ2=6.210, df=1, p=0.013 by allele; χ2=5.03, df=1, p=0.025 by dominant model). Significant allelic association was observed between LEPR rs656451 and CHD among individuals older than 65 years of age (χ2=4.410, df=1, p=0.036). Our study revealed significant associations of APOE, PPAP2B, CETP, MLXIPL, PON2, and LEPR gene polymorphisms with CHD among the Han Chinese. Show less
📄 PDF DOI: 10.14744/AnatolJCardiol.2018.23682
CETP
Zhao Dong, Haozhe Shi, Mingming Zhao +6 more · 2018 · Metabolism: clinical and experimental · Elsevier · added 2026-04-24
Lecithin cholesterol acyltransferase (LCAT) plays a pivotal role in HDL metabolism but its influence on atherosclerosis remains controversial for decades both in animal and clinical studies. Because l Show more
Lecithin cholesterol acyltransferase (LCAT) plays a pivotal role in HDL metabolism but its influence on atherosclerosis remains controversial for decades both in animal and clinical studies. Because lack of cholesteryl ester transfer protein (CETP) is a major difference between murine and humans in lipoprotein metabolism, we aimed to create a novel Syrian Golden hamster model deficient in LCAT activity, which expresses endogenous CETP, to explore its metabolic features and particularly the influence of LCAT on the development of atherosclerosis. CRISPR/CAS9 gene editing system was employed to generate mutant LCAT hamsters. The characteristics of lipid metabolism and the development of atherosclerosis in the mutant hamsters were investigated using various conventional methods in comparison with wild type control animals. Hamsters lacking LCAT activity exhibited pro-atherogenic dyslipidemia as diminished high density lipoprotein (HDL) and ApoAI, hypertriglyceridemia, Chylomicron/VLDL accumulation and significantly increased ApoB100/48. Mechanistic study for hypertriglyceridemia revealed impaired LPL-mediated lipolysis and increased very low density lipoprotein (VLDL) secretion, with upregulation of hepatic genes involved in lipid synthesis and transport. The pro-atherogenic dyslipidemia in mutant hamsters was exacerbated after high fat diet feeding, ultimately leading to near a 3- and 5-fold increase in atherosclerotic lesions by aortic en face and sinus lesion quantitation, respectively. Our findings demonstrate that LCAT deficiency in hamsters develops pro-atherogenic dyslipidemia and promotes atherosclerotic lesion formation. Show less
no PDF DOI: 10.1016/j.metabol.2018.03.003
CETP
C M Schooling, J V Huang, J V Zhao +3 more · 2018 · EBioMedicine · Elsevier · added 2026-04-24
Development of pharmacological treatments to mitigate ischemic heart disease (IHD) has encompassed disappointing results and expensive failures, which has discouraged investment in new approaches to p Show more
Development of pharmacological treatments to mitigate ischemic heart disease (IHD) has encompassed disappointing results and expensive failures, which has discouraged investment in new approaches to prevention and control. New treatments are most likely to be successful if they act on genetically validated targets. We assessed whether existing pharmacological treatments for IHD reduction are acting on genetically validated targets and whether all such targets for IHD are currently being exploited. Genes associated with IHD were obtained from the loci of single nucleotide polymorphisms reported in either of two recent genome wide association studies supplemented by a gene-based analysis (accounting for linkage disequilibrium) of CARDIoGRAMplusC4D 1000 Genomes, a large IHD case (n=60,801)-control (n=123,504) study. Treatments targeting the products of these IHD genes and genes with products targeted by current IHD treatments were obtained from Kyoto Encyclopedia of Genes and Genomes and Drugbank. Cohen's kappa was used to assess agreement. We identified 173 autosomal genes associated with IHD and 236 autosomal genes with products targeted by current IHD treatments, only 8 genes (PCSK9, EDNRA, PLG, LPL, CXCL12, LRP1, CETP and ADORA2A) overlapped, i.e. were both associated with IHD and had products targeted by current IHD treatments. The Cohen's kappa was 0.03. Interventions related to another 29 IHD genes exist, including dietary factors, environmental exposures and existing treatments for other indications. Closer alignment of IHD treatments with genetically validated physiological targets may represent a major opportunity for combating a leading cause of global morbidity and mortality through repurposing existing interventions. Show less
📄 PDF DOI: 10.1016/j.ebiom.2018.01.015
CETP
Chongjia Yan, Song Wang, Jian Wang +6 more · 2018 · Microbiological research · Elsevier · added 2026-04-24
Clioquinol (CQ) has been used as a classical antimicrobial agent for many years. However, its mode of action is still unclear. In our study, the growth of Candida albicans and Saccharomyces cerevisiae Show more
Clioquinol (CQ) has been used as a classical antimicrobial agent for many years. However, its mode of action is still unclear. In our study, the growth of Candida albicans and Saccharomyces cerevisiae was inhibited by CQ. It did not kill yeast cells, but shortened G1 phase and arrested cell cycle at G2/M phase. By using two-dimensional electrophoresis based proteomic approach, six proteins were found to be significantly affected by CQ. Among them, four (PDC1, ADH1, TDH3, IPP1) were up-regulated and the other two (TDH1 and PGK1) were down-regulated. According to the Saccharomyces Genome Database (SGD), these proteins were involved in various biological processes including glycolytic fermentation, gluconeogenesis, glycolytic process, amino acid catabolism, redox reaction and reactive oxygen species metabolic process. It was noted that there was a link between TDH3 and cell cycle. The overexpression of TDH3 phenocopied CQ treatment and arrested the cell cycle at G2/M phase. RT-PCR analysis showed that the mRNA levels of CLN3 and CDC28, critical genes for passage through G1 phase, were up-regulated after the treatment of CQ as well as the overexpression of TDH3. It demonstrates that CQ inhibits the growth of yeast by up-regulating the expression of TDH3 to influence the cell cycle. It is expected to provide new insights for the antimicrobial mechanism of CQ. Show less
no PDF DOI: 10.1016/j.micres.2018.05.006
CLN3
Plinio D Favaro, Xiaojie Huang, Leon Hosang +8 more · 2018 · PLoS biology · PLOS · added 2026-04-24
The disc-large (DLG)-membrane-associated guanylate kinase (MAGUK) family of proteins forms a central signaling hub of the glutamate receptor complex. Among this family, some proteins regulate developm Show more
The disc-large (DLG)-membrane-associated guanylate kinase (MAGUK) family of proteins forms a central signaling hub of the glutamate receptor complex. Among this family, some proteins regulate developmental maturation of glutamatergic synapses, a process vulnerable to aberrations, which may lead to neurodevelopmental disorders. As is typical for paralogs, the DLG-MAGUK proteins postsynaptic density (PSD)-95 and PSD-93 share similar functional domains and were previously thought to regulate glutamatergic synapses similarly. Here, we show that they play opposing roles in glutamatergic synapse maturation. Specifically, PSD-95 promoted, whereas PSD-93 inhibited maturation of immature α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid-type glutamate receptor (AMPAR)-silent synapses in mouse cortex during development. Furthermore, through experience-dependent regulation of its protein levels, PSD-93 directly inhibited PSD-95's promoting effect on silent synapse maturation in the visual cortex. The concerted function of these two paralogs governed the critical period of juvenile ocular dominance plasticity (jODP), and fine-tuned visual perception during development. In contrast to the silent synapse-based mechanism of adjusting visual perception, visual acuity improved by different mechanisms. Thus, by controlling the pace of silent synapse maturation, the opposing but properly balanced actions of PSD-93 and PSD-95 are essential for fine-tuning cortical networks for receptive field integration during developmental critical periods, and imply aberrations in either direction of this process as potential causes for neurodevelopmental disorders. Show less
📄 PDF DOI: 10.1371/journal.pbio.2006838
DLG2
Qianwei Xing, Yeqing Huang, You Wu +2 more · 2018 · PeerJ · added 2026-04-24
Long non-coding RNAs (lncRNAs) play crucial roles in the initiation and progression of renal cell carcinoma (RCC) by competing in binding to miRNAs, and related competitive endogenous RNA (ceRNA) netw Show more
Long non-coding RNAs (lncRNAs) play crucial roles in the initiation and progression of renal cell carcinoma (RCC) by competing in binding to miRNAs, and related competitive endogenous RNA (ceRNA) networks have been constructed in several cancers. However, the coexpression network has been poorly explored in RCC. We collected RCC RNA expression profile data and relevant clinical features from The Cancer Genome Atlas (TCGA). A cluster analysis was explored to show different lncRNA expression patterns. Gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses and gene set enrichment analysis (GSEA) were performed to analyze the functions of the intersecting mRNAs. Targetscan and miRanda bioinformatics algorithms were used to predict potential relationships among RNAs. Univariate Cox proportional hazards regression was conducted to determine the RNA expression levels and survival times. Bioinformatics analysis revealed that the expression profiles of hundreds of aberrantly expressed lncRNAs, miRNAs, and mRNAs were significantly changed between different stages of tumors and non-tumor groups. By combining the data predicted by databases with intersection RNAs, a ceRNA network consisting of 106 lncRNAs, 26 miRNAs and 69 mRNAs was established. Additionally, a protein interaction network revealed the main hub nodes (VEGFA, NTRK2, DLG2, E2F2, MYB and RUNX1). Furthermore, 63 lncRNAs, four miRNAs and 31 mRNAs were significantly associated with overall survival. Our results identified cancer-specific lncRNAs and constructed a ceRNA network for RCC. A survival analysis related to the RNAs revealed candidate biomarkers for further study in RCC. Show less
📄 PDF DOI: 10.7717/peerj.5124
DLG2
Wei-Jun Li, Rui-Xing Yin, Xiao-Li Cao +3 more · 2018 · Lipids in health and disease · BioMed Central · added 2026-04-24
Little is known about the association of the dedicator of cytokinesis 7 (DOCK7 rs1748195) and angiopoietin like 3 (ANGPTL3 rs12563308) single nucleotide polymorphisms (SNPs) and their haplotypes with Show more
Little is known about the association of the dedicator of cytokinesis 7 (DOCK7 rs1748195) and angiopoietin like 3 (ANGPTL3 rs12563308) single nucleotide polymorphisms (SNPs) and their haplotypes with serum lipid levels and the risk of coronary artery disease (CAD) and ischemic stroke (IS) in the Chinese populations. This study aimed to detect such association in a Southern Chinese Han population. This study included 1728 subjects (CAD, 568; IS, 539; and controls, 621). Genotypes of the two SNPs were determined by the Snapshot technology. The genotypic and allelic frequencies of the rs1748195 SNP were different between CAD patients and controls (P < 0.05 for each), the rs1748195G allele frequency was higher in CAD patients than in controls (27.6% vs. 23.6%, P = 0.024). The genotypic frequencies of the rs12563308 SNP were also different between CAD patients and controls (P = 0.021). The rs1748195 SNP was associated with an increased risk of CAD after controlling for potential confounders and Bonferroni correction (P < 0.025 considered statistically significant; Recessive: OR = 1.79, 95% CI = 1.04-3.06, P = 0.017; Log-additive: OR = 1.27, 95% CI = 1.02-1.57, P = 0.014), whereas the rs12563308 SNP was associated with a decreased risk of CAD (Dominant: OR = 0.69, 95% CI = 0.45-0.94, P = 0.011; Log-additive: OR = 0.73, 95% CI = 0.49-0.89, P = 0.009). The rs1748195 SNP was also associated with an increased risk of severity to coronary artery atherosclerosis (Dominant: OR = 1.45, 95% CI = 1.07-2.11, P = 0.017; Log-additive: OR = 1.35, 95% CI = 1.09-1.82, P = 0.013). The interactions of SNP-environment on serum lipid levels and the risk of severity to coronary artery atherosclerosis, CAD and IS were noted. The rs1748195G-rs12563308T haplotype was associated with an increased angiographic severity to coronary artery atherosclerosis (OR = 1.46, 95% CI = 1.05-2.03), and the risk of CAD (OR = 1.37, 95% CI = 1.08-1.74). The interactions of haplotype-hypertension on the risk of CAD and haplotype-drinking on the risk of CAD/IS were observed. These results suggest that the DOCK-ANGPTL3 SNPs and their haplotypes were associated with the angiographic severity to coronary artery atherosclerosis and the risk of CAD and IS in the Southern Chinese Han population. Show less
📄 PDF DOI: 10.1186/s12944-018-0677-9
DOCK7
Ying Ding, Cong Wang, Xuejie Li +13 more · 2018 · Diagnostic pathology · BioMed Central · added 2026-04-24
Metanephric adenoma is a rare, benign renal neoplasm with occasional misdiagnosis. However, its molecular characterization is not fully understood. In this study, we use the hybrid capture-based Next- Show more
Metanephric adenoma is a rare, benign renal neoplasm with occasional misdiagnosis. However, its molecular characterization is not fully understood. In this study, we use the hybrid capture-based Next-Generation Sequencing to sequence a panel of 295 well-established oncogene or tumor suppressor genes in 28 cases of MA patients in China. Novel clinicopathological markers associated with the mitogen-activated protein kinase (MAPK) pathway in metanephric adenoma were detected by immunohistochemistry. It was found that except for BRAF (22/28) mutations (c.1799 T > A, p.V600E), NF1 (6/28), NOTCH1 (5/28), SPEN (5/28), AKT2 (4/28), APC (4/28), ATRX (3/28), and ETV4 (3/28) mutations could also be detected. Meanwhile, a novel and rare gene fusion of STARD9-BRAF, CUX1-BRAF, and LOC100507389-BRAF was detected in one MA patient. In addition, although MEK phosphorylation was normally activated, the phosphorylation level of ERK was low in metanephric adenoma cases. Highly expressed p16 and DUSP6 may have contributed to these results, which maintained MA as a benign renal tumor. This study provides novel molecular and pathological markers for metanephric adenoma, which could improve its diagnosis and increase the understanding of its pathologic mechanism. Show less
📄 PDF DOI: 10.1186/s13000-018-0732-x
DUSP6
Wei-Chan Hsu, Ming-Yu Chen, Shu-Ching Hsu +10 more · 2018 · Proceedings of the National Academy of Sciences of the United States of America · National Academy of Sciences · added 2026-04-24
Activated T cells undergo metabolic reprogramming and effector-cell differentiation but the factors involved are unclear. Utilizing mice lacking DUSP6 (DUSP6
no PDF DOI: 10.1073/pnas.1800076115
DUSP6